Interrogating the role of the novel synaptic protein Rogdi in GABAergic inhibition and epilepsy

NIH RePORTER · NIH · F31 · $33,078 · view on reporter.nih.gov ↗

Abstract

ABSTRACT The pathophysiology of epilepsy is intimately linked with imbalances of excitation and inhibition (E/I) in the brain. Although the loss of GABAergic inhibition is strongly implicated as a mechanism by which E/I imbalances arise in human epilepsy disorders, the molecular mechanisms that govern synaptic inhibition, and thereby maintain E/I balance, have been largely obscure. Recently, we discovered a novel inhibitory synaptic protein, Rogdi, whose gene is strongly linked to a human epilepsy disorder, Kohlschütter-Tönz syndrome. Preliminary data indicate that Rogdi may function either at the pre- or postsynapse where I hypothesize that it may regulate the synaptic vesicle cycle or protein trafficking. I propose to test this hypothesis and demonstrate Rogdi’s functional role at inhibitory synapses. Importantly, I will also determine if the loss of Rogdi is causal for seizures in mice. The successful completion of the proposed research will generate a new preclinical mouse model for studying Kohlschütter-Tönz syndrome and can be expected to generate an understanding of Rogdi’s molecular function and its contribution towards the etiology of a human epilepsy disorder.

Key facts

NIH application ID
9988845
Project number
5F31NS113738-02
Recipient
DUKE UNIVERSITY
Principal Investigator
Tyler Wesley Bradshaw
Activity code
F31
Funding institute
NIH
Fiscal year
2020
Award amount
$33,078
Award type
5
Project period
2019-07-01 → 2021-04-30